What is Embryology? – news-medical.net

Embryology is the study of development of an embryo from the stage of ovum fertilization through to the fetal stage.

The ball of dividing cells that results after fertilization is termed an embryo for eight weeks and from nine weeks after fertilization, the term used is fetus.

Once an egg is released from the ovary during ovulation, it meets with a sperm cell that was carried to it via the semen. These two gametes combine to form a zygote and this process is called fertilization. The zygote then begins to divide and becomes a blastula.

The blastula develops in one of two ways, which actually divides the whole animal kingdom in half. The blastula develops a pore at one end, called a blastopore. If that blastopore becomes the mouth of the animal, the animal is a protostome, and if it forms an anus, the animal is a deuterostome.

Protosomes are invertebrate animals such as worms, insects and molluscs while deuterostomes are vertebrates such as birds, reptiles, and humans.

The blastula continues to develop, eventually forming a structure called the gastrula. The gastrula then forms three germ cell layers, from which all of the bodys organs and tissues are eventually derived. From the innermost layer or endoderm, the digestive organs, lungs and bladder develop; the skeleton, blood vessels and muscles are derived from the middle layer or mesoderm and the outer layer or ectoderm gives rise to the nervous system, skin and hair.

Reviewed by Sally Robertson, BSc

Originally posted here:
What is Embryology? - news-medical.net

Dr Brian Iddon details his life as a Bolton MP in second volume of … – The Bolton News

FROM being put into stocks in Bolton to campaigning to ensure people with Downs Syndrome are not discriminated against, Dr Brian Iddon has given a detailed insight into his life as a Bolton MP in the second volume of Science & Politics: An Unlikely Mixture.

Volume One of Dr Iddons autobiography was published in 2015 in which he told of his remarkable career as a scientist and, in his recently released second part, he explains how he found himself representing Bolton South East at Westminster for three years.

Volume Two is billed as the most detailed account of a Parliamentary career written in modern times by a back-bench MP and, says Dr Iddon, has been written to help dispel the myth that MPs have an easy life.

He said: A lot of people do not know what MPs do. That is why I have produced this - we have family lives as well.

Some MPs are lazy but I did not want to be like that I wanted to go to Parliament and do something.

It was killing me, the pace I was going, I could not keep it up. It was my fault I got involved in far too many things and I went to too many meetings. I was just weighed down in the end.

I was almost 70 when I retired. I promised myself that I would go at 70. I wanted a life beyond Parliament, but my constituency members wanted me to do at least one more term, which was nice.

He added: Volume One of the autobiography is all about my chemistry career, my education and early life in the village of Tarleton. Volume Two is all about my political career and the rest of my family life.

Its is a heftier tome than first one was but there is a lot of humour in the book.

The opening chapter of the book is about Dr Iddons move to Bolton in 1972 in the Firwood Fold area, from Boothstown.

I came to Bolton because I loved the people, and the service in the shops was exceptional. People talked to you in the shops, he said.

Thats what brought me to Bolton, the friendliness of the people.

Dr Iddon writes about how he became involved in community politics after he disagreed with changes in his neighbourhood and started Tonge Moor Residents Association.

He said: I was a member of the Labour Party when I came here and joined Tonge Ward Labour Club.

My family has always been Labour and my family has always been immersed in the community.

He soon became vice-chairman and chairman of the local constituency party and found himself standing in local elections after the candidate who had been selected forgot to sign important paperwork and had gone on a pilgrimage to Lourdes.

But it was not until 1977 that he was elected councillor for Church, East and North Ward, which until then had been strongly Conservative.

I won accidentally, third time lucky, he said.

During his council years he started Bolton Bond Board, which celebrates its 25th anniversary next year, and Careline, which is now run by Bolton at Home. The first public sector neighbourhood dispute service, which he proposed be set up in Bolton, has been extended.

Dr Iddon and his colleagues would help out in other ways.

He said: I dressed up as Biggles and we did all kinds of things to raise money for charity, usually Mencap.

There would be a flan a councillor day. We built some stocks or borrowed some and put them in the precinct and gave people custard pies.

They had to pay a fortune for shoving one in our face but some people were nasty and banged them in our faces. We produced ducking stools for a duck a councillor day we did all this stuff in the 70s.

Dr Iddon said: I built my entire political career on what I did in Bolton but I was never seeking a Parliamentary seat.

Councillors, party members and members of the public kept asking me to stand for Parliament. I had been asked why I wouldnt stand 1,000 times. In the end I thought where am I going at Salford University?

It was a big decision but I took it. I wouldnt have done it in a marginal seat, because I was loving what I was doing at the time and it was a big change in direction.

He was elected to the safe Labour seat with a 21,311 majority in 1997 after the previous sitting Labour MP, David Young was deselected by the constituency.

As MP, Dr Iddon enlisted the help of John Prescott to allow Fred Dibnah to operate his house as a museum - producing smoke legally.

He also enhanced protection for tenants, who would find themselves homeless because the landlord had defaulted on mortgage payments.

Dr Iddon said: In Westminster I got three Acts of Parliament through.

I am proud of my case work what we did for people like putting the Womens Land Army on the map, getting Fred Dibnah his licence, even if he was a Tory all his life

The most important piece of work I was involved with was The Human Fertilisation and Embryology Act.

We realised that the technology was way ahead of the legislation.

Practitioners were doing things that hadnt been legalised. They were not illegal, but some people considered they were immoral. It was ethics versus science and we had to put this right. It was one of the most controversial bills ever considered during my 13 years in Parliament.

Dr Iddon also helped put an end to people with Downs Syndrome being denied medical treatment and the European Parliament from getting rid of MRI scanners the only European regulation or directive that I have known to be stopped and it was rejigged because of us, said Dr Iddon.

He said: The best part of the job was being able to open doors for people.

I miss the excitement. Parliament is an exciting place there were no dull days.

I miss being able to help people. Thats the reason I went down in the first place and boy did we help people thousands of them.

I could write another book about that but I cant, I am sworn to secrecy.

I feel immensely privileged to have served in Parliament.

More:
Dr Brian Iddon details his life as a Bolton MP in second volume of ... - The Bolton News

Shire launches new ADHD drug Mydayis as it weighs a neuroscience exit – FiercePharma

Despite earlier this month announcing its considering a sale of ADHD offerings, Shire has launched its latest Adderall formulation in the U.S. The company on Monday started selling Mydayis at a price of $271 per month before rebates and discounts, hoping to achieve $500 million in annual sales.

Shire had been marketing its new medication on a limited basis, but nowthe rollout has begun in earnest. It includes a copay offer for commercially insured patients, according to a release. In an interview, Shires head of global communications for ophthalmics and neuroscience, Clotilde Houz, said the launch provides the ADHD community a new treatment option.

We know that not all patients respond to medications in the same way, Houz said. We really want to support physicians and patients who might want different treatment options.

Mydayis won approval back in June based on 16 clinical trials incorporating more than 1,600 participants. The once-daily medication helped patients scores on a validated attention test, with effects starting within 2 to 4 hours and lasting up to 16 hours, according to the drugmaker. Mydayis is approved for ADHD patients 13 and older.

RELATED: Can Shire's new Mydayis, its latest Adderall iteration, really nab $500M in sales?

Weve been working since the FDA approval to properly train our salesforce and make sure that they have all of the information needed to talk to the physicians, Houz said, without disclosing how many representatives are supporting the launch.

She added that the 16-hour effect for Mydayis may be a benefit physicians seek out for treating their patients.

Sales expectations are mixed on the new drug, with the companys own thoughts coming in ahead of Wall Streets. At the time of approval, consensus analyst projections were for $288 million in sales by 2020, significantly short of Shires aspirations of $500 million for that year.

Shire priced its drug competitively and in consideration of the innovation and value it delivers, according to a company statement. Payer negotiations are ongoing, Houz said, adding that the company looks forward to sharing more news on that in the future.

To reach its $500 million sales ambition for 2020, Shire has said itll lean on its leadership position and experience in ADHD. Since the FDA approval for Mydayis, however, the Irish drugmaker has disclosed it may be looking to get out of neuroscience altogether.

RELATED: Shire hints at ADHD spinoff, but could someone step in and buy the neuro franchise?

In its second-quarter earnings announcement, the drugmaker disclosed its assessing strategic options for the group, potentially including an independent public listing. During the quarter, Vyvanse sales stayed flat versus the prior year at $518 million, while Adderall XR slipped 30% to $71 million.

Mydayis FDA approval followed a green light at the agency for Neos Therapeutics Cotempla, an extended-release ADHD drug that melts in the mouth. More than 10 million adults have ADHD in the U.S., according to Shire.

The company will continue its disease awareness campaign, but because Mydayis is a class 2 stimulant, Shire needs to await FDA guidance for DTC advertising, Houz said.

The rest is here:
Shire launches new ADHD drug Mydayis as it weighs a neuroscience exit - FiercePharma

Genetics put some older women at higher risk than men for Alzheimer’s – USC News

White women whose genetic makeup puts them at higher risk for Alzheimers disease are more likely than white men to develop the disease during a critical 10-year span in their lives, according to a study headed by Keck School of Medicine of USC researchers.

The findings from one of the worlds largest big-data studies on Alzheimers counter long-held beliefs about who is at greatest risk for the disease and when, suggesting new avenues for clinical trials.

Study results show genetically vulnerable 55- to 85-year-old white men and women have the same odds of developing the memory-erasing disease. One exception: From their mid-60s to mid-70s, these women still face significantly higher risk. That may provide clues to disease causes and potential interventions among these women.

Our discovery is important because it highlights how clinical trials could be weighted toward women a susceptible part of the population to help scientists more rapidly identify effective drug interventions to slow or cure Alzheimers, said Arthur Toga, director of the USC Stevens Neuroimaging and Informatics Institute at the Keck School of Medicine among the nations leaders in innovative scientific discovery.

The study was published Aug. 28 in the Journal of the American Medical Association Neurology. It included data from 57,979 North Americans and Europeans in the Global Alzheimers Association Interactive Network (GAAIN). This big-data project provides scientists around the world with shared data and sophisticated analysis tools to address a disease that makes up about 65 percent of the 47 million cases of dementia worldwide.

The results contradict a seminal 20-year-old study that found women with one copy of ApoE4, a gene variant linked to Alzheimers, were diagnosed with the disease 50 percent more often than men with the same genetic profile.

The findings presented in the USC-led study expand the number of participant data by ninefold and indicate the critical decade falls between 65 and 75, more than 10 years after the start of menopause. Previous studies in animals and humans have reported a relationship between ApoE4, menopause and cognitive decline.

So much work has been dependent on one 1997 finding, but with tools like GAAIN, we now have the ability to reinvestigate with increased statistical power, Toga said.

The new findings are significant because almost two-thirds of the more than 5 million Americans now with Alzheimers disease today are women.

The new findings are significant because almost two-thirds of the more than 5 million Americans now living with Alzheimers disease are women, according to the Alzheimers Association.

Many attribute the imbalance in disease risk to the fact that women, on average, live longer than men. However, a growing body of evidence suggests other reasons also contribute to the difference. For instance, men have higher rates of heart disease and stroke. So, men who live longer may be healthier than women of the same age and may face less risk of developing Alzheimers, according to the USC-led study.

In the future, doctors who want to prevent Alzheimers may intervene at different ages for men and women, said Judy Pa, co-author of the study and an assistant professor of neurology at the USC Stevens Neuroimaging and Informatics Institute.

Menopause and plummeting estrogen levels, which on average begins at 51, may account for the difference, Pa said. However, scientists still dont know what is responsible. Researchers need to study women 10, 15 or even 20 years before their most vulnerable period to see if there are any detectable signals to suggest increased risk for Alzheimers in 15 years.

Only some women are at increased risk of developing Alzheimers in their mid-60s to mid-70s compared to men. To find out, women could have their DNA analyzed. However, Pa cautions that genetic testing for the ApoE4 variant is no crystal ball.

There is controversy in terms of whether people should know their ApoE status because it is just a risk factor, Pa said. It doesnt mean youre going to get Alzheimers disease. Even if you carry two copies of ApoE4, your chances are greatly increased, but you could still live a long life and never have symptoms.

Even if some women discover they are at heightened risk, they can improve their odds by making life changes.

Get more exercise. Work out your mind, especially in old age.

Judy Pa

Get more exercise. Work out your mind, especially in old age, Pa said. Pick up hobbies that are cognitively or physically challenging. Reduce processed sugar intake because its linked to obesity, which is associated with many chronic diseases.

Alzheimers disease is the fifth-leading cause of death for Americans 65 and older, but it may one day outpace the nations top two killers heart disease and cancer. Alzheimers-related deaths increased by nearly 39 percent between 2000 and 2010 while heart disease-related deaths declined 31 percent and cancer deaths fell 32 percent, according to the Centers for Disease Control and Prevention.

Because Alzheimers disease has a huge impact on lifelong health, USC has more than 70 researchers dedicated to the prevention, treatment and potential cure of the memory-erasing disease. Big data projects like this require experts across disciplines computer science, biology, pathophysiology, imaging and genetics to coordinate.

For this study, the researchers examined data from 27 different studies that assessed participants ApoE gene variation, as well as characteristics such as sex, race, ethnicity, diagnosis (normal, mild cognitive impairment or Alzheimers disease) and age at diagnosis.

The records of nearly 58,000 people were scrutinized. Meta-analyses were performed on 31,340 whites who received clinical diagnoses sometime between ages 55 and 85.

The proportion of minorities was so small that analysts could not draw statistically significant conclusions about their disease risk. Because of this, the study focused on whites only.

Most of the archives around the world have insufficient numbers of underrepresented groups, Toga said. One of the take-home messages from our study is people of all races and ethnicities need to be involved in Alzheimers clinical trials because this disease is a problem that affects all of us.

The current findings need to be confirmed in more diverse study populations.

USC is working to build more diverse population studies related to Alzheimers. Established in 1984, the Alzheimer Disease Research Center at the Keck School of Medicine reaches out to communities in the greater Los Angeles area to educate the citys diverse population about Alzheimers and the clinical trials they might be interested in joining. Previous studies, for example, have focused on Latinos.

Historically, women have not been adequately represented in clinical trials, especially in studies on heart disease. Women need to be represented equally to men or even overrepresented, Pa said.

The bottom line is women are not little men, Pa said. A lot more research needs to target women because gender-specific variations can be so subtle that scientists often miss them when they control for gender or use models to rule out gender differences. Most research today is ignoring a big part of the equation.

The study was made possible because of lead author Scott Neu, a leader in the development of a federated approach to analyzing metadata and assistant professor of research at the Laboratory of Neuro Imaging at the Keck School of Medicine.

GAAIN the free resource we created in conjunction with the Alzheimers Association allows anyone to explore data sets around the world and conduct preliminary analyses to test scientific hypotheses, Neu said. Our goal is to connect scientists with those who have collected data to create new collaborations to further research and understanding of Alzheimers disease.

Analysts excluded people with a history of stroke, cerebrovascular disease, abnormal proteins that contribute to Parkinsons disease and dementia, gene mutations leading to higher levels of toxic amyloid brain plaques and any known neurological diseases.

Scientists did not adjust for known Alzheimers risk factors such as education, family history of Alzheimers or dementia because that information was not provided in all data sets. They also were unable to adjust for sex-dependent differences such as cigarette smoking, hormonal changes with age and alcohol usage.

The study was supported by the Alzheimers Association through the Global Alzheimers Association Interactive Network initiative (GAAIN-14-244631) via a $5 million grant and a portion of two National Institutes of Health grants: $12 million from Big Data to Knowledge (U54-EB020406) and $5 million from neuroimaging and genetics (P41-EB015922).

More stories about: Alzheimer's Disease, Research

Go here to read the rest:
Genetics put some older women at higher risk than men for Alzheimer's - USC News

Hospital to boost genetic testing for newborn babies – Belfast Telegraph

Hospital to boost genetic testing for newborn babies

BelfastTelegraph.co.uk

One of the UK's largest women's hospitals is to increase its ability to genetically test newborn babies 12-fold.

http://www.belfasttelegraph.co.uk/news/northern-ireland/hospital-to-boost-genetic-testing-for-newborn-babies-36079324.html

http://www.belfasttelegraph.co.uk/news/northern-ireland/article36079323.ece/c3338/AUTOCROP/h342/PANews%20BT_P-013b5e7c-4e66-4b0a-b8d6-04b3c11abd37_I1.jpg

One of the UK's largest women's hospitals is to increase its ability to genetically test newborn babies 12-fold.

Liverpool Women's NHS Foundation Trust will be able to screen all infants for inherited conditions or illnesses and plan for early treatment as part of a major new IT project.

It will also contribute to a major population health programme in Liverpool analysing genetic information by location, identifying and enabling work to prevent localised health issues.

IT firm Novosco will introduce the computing system.

Novosco managing director Patrick McAliskey said: "We are delighted to secure this contract which will enable the trust to take genetic testing to the next level and play an important role in the identification and prevention of conditions and illnesses in new-born babies and the wider population."

This role of genetics in healthcare is one of the most rapidly expanding areas of development for Liverpool Women's.

It provides a regional clinical genetics service based at Alder Hey Hospital, covering a population of around 2.8 million people from across Merseyside, Cheshire and the Isle of Man, chief executive Kathryn Thomson posted on the trust's website.

She added: "To discover that you or any child you have or plan to have may be at risk of a genetic disorder which could cause disability or a rare condition is traumatic.

"People are sometimes shocked and anxious and wonder what the future might hold.

"They need as much information and support as possible to help them cope.

"That is why the often unsung work of our clinical genetics team is so important, providing diagnosis and supporting families when they need it most."

Liverpool Women's NHS Foundation Trust specialises in the health of women and their babies - both within the hospital and in the community. It is one of only two such specialist trusts in the UK - and the largest women's hospital of its kind.

Novosco is an IT infrastructure and managed cloud computing company and employs over 150 people. It has its headquarters in Belfast, with offices in Manchester, Dublin, and Cork.

See the original post here:
Hospital to boost genetic testing for newborn babies - Belfast Telegraph

New Genetics: The Gold Seal of Approval – Cannabis Now

Nightmare Cookies | Photos Ron Goldman via Stock Pot Images

While youve probably never encountered strains like Gorilla Grip or Nightmare Cookies, Goldman and a select group of other growers have been diligently laboring over trial gardens scanning them for anomalies and difficulties or possibly the next cannabis superstar like Northern Lights or Jack Herer.

I really like pushing the boundaries to get plants to reach their full genetic potential, he says.

Strain: Frozen Tangerines

A cannabis cultivator with overfour decades of experience, Goldmans initial farming experience began as a grower of greenhouse produce in the 1980s. More recently,his talents have been sought after by a number of marijuana seed breeders looking totest out new creations.

The same way that most manufacturers put their products through rigorous testing, says Goldman, cannabis seeds need to be tested toobefore theyre released to the world.

Because breeders are basically putting their reputations on the line every time they release a newly developed strain, testers like Goldman are absolutely essential to the process. The seed sellers that he consults for want to hear all the pros and cons of their new strains how they handle heat, synthetic versus organic fertilizers or small versus large habitats. They want a full picture of the plants inherent strengths, weaknesses and peculiarities to know whether its back to the drawing board or ready for consumer release.

Strain: Purple Frog

With every trial run, Goldman creates a detailed grow log from the time seeds germinate all the way through harvest. Being an avid photographer and a teacher of photography besides all of his very detailed scientific methodology is accompanied by close photo documentation week after week as the plants mature.

Ill document the structure of the plant and flowers. Looking at things like flower density and calyx to leaf ratio as well as yield and cannabinoid levels.

Some of Goldmans most recent work has been with Sin City Seeds, testing potential new releases such as Nightmare Cookies, a cross of White Nightmare and Platinum Girl Scout Cookies. He says its not only a beautiful plant with rich colors but at 26 percent THC, it packs a potent punch.

Strain: West Seattle

With Washington state now allowing medical and recreational cultivation, says Goldman, I can legally put together my passion for photography with my passion for growing.

The following photos were all taken from Goldmans medical cannabis test gardens and are strains we hope the public will soon have a chance to sample.

Originally published in Issue 18 of Cannabis Now. LEARN MORE

TELL US,does cannabis breeding interest you?

See the article here:
New Genetics: The Gold Seal of Approval - Cannabis Now

UAH welcomes Dr. Sharifa Love-Rutledge to the College of Science – UAH News (press release)

Dr. Sharifa Love-Rutledge is a new faculty member in the UAH College of Science.

Michael Mercier | UAH

Sharifa Love-Rutledge developed a keen interest in science when she and her younger brother shared a lab kit for Christmas one year. "We made borax (super bouncy) balls first, and went on to complete all the experiments in the kit, and I wanted to do more," said Love-Rutledge, an incoming faculty member at The University of Alabama in Huntsville (UAH) College of Science. She is also the first African-American woman to earn a PhD from The University of Alabama Department of Chemistry.

When Love-Rutledge entered college, she started out as a biology major, but after completing general chemistry and organic chemistry courses, she made the "switch" to chemistry.

"I was drawn to chemistry because of my love for creative problem-solving. Biochemistry was the subject that allowed me to utilize my analytical thought processes to pursue biological questions. It didn't dawn on me that chemistry was a male dominated field until graduate school. By then, it was too late because I was already hooked."

A native of Moss Point, MS, Love-Rutledge attended Moss Point High School. An Advanced Placement student in English and Mathematics, she went on to graduate from Tougaloo College (Tougaloo, MS) with a Bachelor of Science degree in Chemistry. Love-Rutledge earned a Master's degree and PhD from The University of Alabama (UA) in Chemistry and Biochemistry, respectively.

Love-Rutledge said she "felt hopeful," when she realized she would be the first African American woman to earn a PhD in chemistry from UA. "It was bittersweet because the reality of it all is that I wasn't the first African American female capable of the accomplishment but opportunities weren't afforded in the past. It allowed me to view myself as part of the culmination of the sacrifices made by those like Vivian Malone and James Hood," she added.

The student in lockstep with Love-Rutledge in the Department of Chemistry at UA was Dr. Melody Kelley, now Assistant Professor of Chemistry at Georgia State University. Love-Rutledge said she continues to find "inspiration in seeing other African American women who are persevering and making progress toward the completion of advanced degrees."

Early mentors for Love-Rutledge were her older siblings. "They poured their knowledge into me to ensure that I made wise decisions. If it wasn't for my older brother, I don't think I would've survived some of my math courses," she said. "Once I left home, I started to rely on advice from my uncle Dr. Claude McGowan, who was Director of Toxicology at Johnson & Johnson, along with professors like Dr. Candice Love-Jackson, Acting Provost and Vice President for Academic Affairs at Kentucky State University."

Additionally, Love-Rutledge was encouraged through the graduate school application process by dedicated Ronald McNair Scholars Coordinator, Demetria Hereford. And, as a graduate student, she was able to enlist the tutelage of several professors at UA. "It was also in graduate school that I was reminded of how important my parents' guidance is. Their constant support and dedication was important in forming my personal and professional abilities."

Love-Rutledge learned about UAH from Dr. Emanuel Waddell, Associate Dean of the College of Science while attending graduate school at UA. "The deciding factors for me to further my teaching and research career at UAH included the size of the student population and access to resources that I would need to be successful. I have always wanted to work at a university where students are viewed as more than numbers."

"We are excited to have Dr. Love-Rutledge join us in the chemistry department. Her research will be attractive to students and we look forward to her establishing her research laboratory in the coming months," said Dr. Emanuel Waddell, Associate Dean of the UAH College of Science.

At UAH Love-Rutledge will teach biochemistry classes. "I have a lab and I am currently working on research projects related to identifying biomarkers for Type 1 Diabetes, and studying the changes cells producing insulin undergo before disease onset." As a teacher, Love-Rutledge said she loves students' lightbulb moments the best. At UA she served as a graduate teaching assistant for the majority of her graduate career. "I love reaffirming students' passion for their chosen field of study. There is no greater joy for me than to see my students go on to be successful in their fields of choice. I have taught students who wanted to be nurses and are nurses now, and students who wanted to be doctors who are now in residency programs. I love seeing students reach their goals."

As a Ronald E. McNair Scholar, Love-Rutledge's first bona fide research project studied the enzymes that activate colon cancer drugs. The project's Principal Investigator was Dr. Randy Wadkins, Associate Professor of Chemistry and Biochemistry at The University of Mississippi. "In my graduate research, I worked on projects that helped show Chromium, (hard, brittle metal) is not an essential element for mammalian nutrition. The research findings were published in a paper that led The European Food and Safety Authority to remove Chromium from the list of elements that 'require daily intake'."

Love-Rutledge freely offers words of wisdom for young women interested in entering academic fields of specialization. "Recently Ive been exposed to the slogan, 'You cant do UAH alone'. I think it's awesome advice for young women to adapt who are interested in chemistry 'You cant do Chemistry alone'," she said. "Even when you seem alone, you never are. Find mentors to give you advice, utilize your peers on and off campus to get through the tough times. Some of my best academic advice came from taking a risk and emailing a professor who I thought was out of reach. You will be surprised at how much help you could receive if you just ask for it."

***EDITOR'S NOTE: The McNair Scholars Program is a federal program funded at 51 institutions across the United States and Puerto Rico by the U.S. Department of Education. It is designed to prepare undergraduate students for doctoral studies through involvement in research and other scholarly activities. Dr. Ronald E. McNair was the second African American to fly in space. Two years later he was selected to serve as mission specialist aboard the ill-fated U.S. Challenger space shuttle. He was killed on Jan. 28, 1986, instantly when the Challenger exploded one minute, 13 seconds after it was launched.

See the original post:
UAH welcomes Dr. Sharifa Love-Rutledge to the College of Science - UAH News (press release)

Scientist expects biomed research to remain focused on antibodies – Focus Taiwan News Channel

Taipei, Aug. 28 (CNA) Antibody and small molecule drugs and big data applications will remain at the center of biomedical research in the future, according to Andrew Wang (), president-elect of the International Union of Biochemistry and Molecular Biology (IUBMB).

Wang was speaking on the future development of biomedical technology in a recent interview with CNA, in which he encouraged local scientists to find the right directions if they decide to devote themselves to antibody drug research and development.

Biomedicine is an emerging sector that has attracted many scientists around the world, said the chemist, who serves as the distinguished visiting chair of the Institute of Biological Chemistry at Academia Sinica, Taiwan's top academic research institution.

Wang also encouraged researchers to seek new techniques, citing the example of French scientist Emmanuelle Charpentier and Americans Jennifer A. Doudna and Feng Zhang (), the trio who shared the 2016 Tang Prize for biopharmaceutical science.

They were honored for the development of the CRISPR/Cas9, a genome editing tool that enables geneticists and medical researchers to edit DNA, using a technique that has the potential for a wide range of applications, according to the Tang Prize Foundation.

Wang praised the CRISPR/Cas9 as a big breakthrough, and he expected it to significantly affect future research, which he said could even reach the aspect of biological transformation.

"In the future, cell therapies will become very important," Wang said.

In addition to antibody and small molecule drug research, changes in medical treatment methods are a direction that local scientists can also turn to, Wang said, noting that the results of big data analysis related to health insurance practices can be applied in the precision medicine sector.

The Tang Prize awards were established by Taiwanese entrepreneur Samuel Yin () in 2012 to honor people who have made significant contributions in the fields of sustainable development, biopharmaceutical science, sinology and rule of law. They are dubbed as the "Asian Nobel Prize."

The IUBMB is an international non-governmental organization concerned with biochemistry and molecular biology. Founded in 1955, it unites biochemists and molecular biologists in 75 countries that belong to the union as an adhering body or associate adhering body represented by a biochemical society, a national research council or an academy of sciences.

(By Yu Hsiao-han and Elizabeth Hsu)Enditem/sc

Read more:
Scientist expects biomed research to remain focused on antibodies - Focus Taiwan News Channel

FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments – NPR

Adult stem cells can be extracted from human fat. Patrick T. Fallon /The Washington Post/Getty Images hide caption

Adult stem cells can be extracted from human fat.

The Food and Drug Administration is cracking down on "unscrupulous" clinics selling unproven and potentially dangerous treatments involving stem cells.

Hundreds of clinics around the country have started selling stem cell therapies that supposedly use stem cells but have not been approved as safe and effective by the FDA, according to the agency.

"There are a small number of unscrupulous actors who have seized on the clinical promise of regenerative medicine, while exploiting the uncertainty, in order to make deceptive, and sometimes corrupt assurances to patients based on unproven and, in some cases, dangerously dubious products," FDA Commissioner Scott Gottlieb said in a statement Monday.

The FDA has taken action against clinics in California and Florida.

The agency sent a warning letter to the US Stem Cell Clinic of Sunrise, Fla., and its chief scientific officer, Kristin Comella, for "marketing stem cell products without FDA approval and significant deviations from current good manufacturing practice requirements."

The clinic is one of many around the country that claim to use stem cells derived from a person's own fat to treat a variety of conditions, including Parkinson's disease, amyotrophic lateral sclerosis (ALS), and lung and heart diseases, the FDA says.

The Florida clinic had been previously linked to several cases of blindness caused by attempts to use fat stem cells to treat macular degeneration.

The FDA also said it has taken "decisive action" to "prevent the use of a potentially dangerous and unproven treatment" offered by StemImmune Inc. of San Diego, Calif., and administered to patients at California Stem Cell Treatment Centers in Rancho Mirage and Beverly Hills, Calif.

As part of that action, the U.S. Marshals Service seized five vials of live vaccinia virus vaccine that is supposed to be reserved for people at high risk for smallpox but was being used as part of a stem-cell treatment for cancer, according to the FDA. "The unproven and potentially dangerous treatment was being injected intravenously and directly into patients' tumors," according to an FDA statement.

Smallpox essentially has been eradicated from the planet, but samples are kept in reserve in the U.S. and Russia, and vaccines are kept on hand as a result.

But Elliot Lander, medical director of the California Stem Cell Treatment Centers, denounced the FDA's actions in an interview with Shots.

"I think it's egregious," Lander says. "I think they made a mistake. I'm really baffled by this."

While his clinics do charge some patients for treatments that use stem cells derived from fat, Lander says, none of the cancer patients were charged and the treatments were administered as part of a carefully designed research study.

"Nobody was charged a single penny," Lander says. "We're just trying to move the field forward."

In a written statement, U.S. Stem Cell also defended its activities.

"The safety and health of our patients are our number one priority and the strict standards that we have in place follow the laws of the Food and Drug Administration," according to the statement.

"We have helped thousands of patients harness their own healing potential," the statement says. "It would be a mistake to limit these therapies from patients who need them when we are adhering to top industry standards."

But stem-cell researchers praised the FDA's actions.

"This is spectacular," says George Daley, dean of the Harvard Medical School and a leading stem-cell researcher. "This is the right thing to do."

Daley praised the FDA's promise to provide clear guidance soon for vetting legitimate stem-cell therapies while cracking down on "snake-oil salesmen" marketing unproven treatments.

Stem-cell research is "a major revolution in medicine. It's bound to ultimately deliver cures," Daley says. "But it's so early in the field," he adds. "Unfortunately, there are unscrupulous practitioners and clinics that are marketing therapies to patients, often at great expense, that haven't been proven to work and may be unsafe."

Others agreed.

"I see this is a major, positive step by the FDA," says Paul Knoepfler, a professor of cell biology at the University of of California, Davis, who has documented the proliferation of stem-cell clinics.

"I'm hoping that this signals a historic shift by the FDA to tackle the big problem of stem-cell clinics selling unapproved and sometimes dangerous stem cell "treatments" that may not be real treatments," Knoepfler says.

Go here to read the rest:
FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments - NPR

Cancer breakthrough: Scientists discovery new process which triggers death of cancer cells – Express.co.uk

GETTY

The team of British researchers believe the groundbreaking method could shrink tumours and be more effective than any other existing treatments - such as chemotherapy.

The new process which kills off cancer cells has been called Caspase Independent Cell Death (CICD) and in trials led to the complete eradication of tumours in experimental models.

Scientists now believe the groundbreaking new research, published in Nature Cell Biology, could revolutionise the way cancer is tackled.

Lead author Dr Stephen Tait, from the University of Glasgow, explained: We were interested in identifying an alternative way to kill cancer cells. And weve identified a process called Caspase Independent Cell Death that appears, really excitingly, to be more effective (than other current methods).

Currently, most anti-cancer therapies - chemotherapy, radiation and immunotherapy - work by killing cancer cells through a process called apoptosis, which activates proteins called caspases, leading to cell death.

We were interested in identifying an alternative way to kill cancer cells

Lead author Dr Stephen Tait

But in apoptosis, therapies often fail to kill all the cancer cells, leading to disease recurrence, and can also have unwanted side effects that may even promote cancer.

The scientists at the University of Glasgow wanted to develop a way to improve therapy that induces cancer cell killing while also mitigating unwanted toxicity.

Announcing the successful new process, Dr Tait, also of the Cancer Research UK Beatson Institute, Institute of Cancer Sciences, said: Our research found that triggering Caspase-Independent Cell Death (CICD), but not apoptosis, often led to complete tumour regression.

Especially under conditions of partial therapeutic response, as our experiments mimic, our data suggests that triggering tumour-specific CICD, rather than apoptosis, may be a more effective way to treat cancer.

Unlike apoptosis, which is a silent form of cell death, when cancer cells die through CICD, they alert the immune system through the release of inflammatory proteins.

The immune system can then attack the remaining tumour cells that evaded initial therapy-induced death.

The researchers used lab-grown colorectal cancer cells to show the advantage of killing cancer cells via CICD, however, these benefits may be applicable to a wide-range of cancer types.

Getty Images

1 of 11

How to prevent skin cancer

Dr Tait added: In essence, this mechanism has the potential to dramatically improve the effectiveness of anticancer therapy and reduce unwanted toxicity.

"Taking into consideration our findings, we propose that engaging CICD as a means of anti-cancer therapy warrants further investigation.

And he explained why it could be more effective than existing traditional treatments such as chemotherapy or radiotherapy.

He said: What we found in essence is the cells that undergo Caspase Independent Cell Death, they stimulate an immune response against the rest of the rumour.

In effect, you dont necessarily need to kill all the tumour cells with therapy because weve now elicited an immune response that then clears out the remaining tumour - in doing so eradicating the cancer.

GETTY

Latest figures show that half of all Britons born after 1960 will be diagnosed with some form of cancer during their lifetime.

Experts say four in 10 cancer cases are linked to lifestyle factors.

Smoking remains the largest single preventable cause.

More than half of cancer deaths in the UK are of people aged 75 years and over.

Last night, cancer research bodies in the UK gave the new research a warm welcome.

GETTY

Dr Justine Alford, Cancer Research UKs senior science information officer, said: Although many cancer treatments work by triggering apoptosis, that method sometimes fails to finish the job and instead may lead to the tumour becoming harder to treat.

And she added: This new research suggests there could be a better way to kill cancer cells which, as an added bonus, also activates the immune system.

Now scientists need to investigate this idea further and, if further studies confirm it is effective, develop ways to trigger this particular route of cell death in humans.

The new paper is published in Nature Cell Biology.

The paper was majority funded by Cancer Research UK.

Read the original post:
Cancer breakthrough: Scientists discovery new process which triggers death of cancer cells - Express.co.uk